Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta has announced to leverage Biotalys’ AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG has got a €600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
European life sciences venture capital company Forbion has raised two oversubscribed funds totalling €1.35 bn.
German radiopharmaceuticals developer Ariceum Therapeutics has raised a further €22.75m extension of its €25m Series A financing announced in June 2022.
Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Swiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.
Ultrasound that switches cancer drug on could significantly reduce chemotherapy side effects, German researchers found in preclinical studies.
At the beginning of April, the FAO presented a report entitled "Food safety aspects of cell-based food" to establish safety standards for cell-based proteins.
Wellcome Sanger Institute spin out Mosaic Therapeutics has closed a $28m series A funding led by Syncona Investment Management Ltd, and Cambridge Innovation Capital.